PatientsHCP
This site is for US Health Care Professionals only.

ENTRESTO® has a proven safety profile comparable to an ACEi and an ARB1

PARADIGM-HF: ENTRESTO has safety comparable to enalapril in patients with HFrEF
Adverse reactions reported in ≥5% of patients treated with ENTRESTO in the double-blind period†
Adverse Reactions Graph
*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1
†Due to the run-in period, adverse event rates were lower than would be expected in practice.

No new safety signals were observed in patients with HFpEF* with LVEF below normal1
In PARAGON-HF, the safety of ENTRESTO was comparable to valsartan.

Download to see renal safety profile across 3 clinical trials
Download the Renal Safety Flashcard to learn more

Starting your patients on ENTRESTO

SEE DOSING

Learn about the dual mechanism of action of ENTRESTO

SEE DUAL MOA

Discover support and resources to help your patients start on ENTRESTO

GET SUPPORT & RESOURCES

Definitions
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LAE, left atrial enlargement; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; MOA, mechanism of action.

Reference
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.